NMC
NEA Management Company Portfolio holdings
AUM
$1.33B
This Quarter Return
+5.79%
1 Year Return
+85.82%
3 Year Return
+531.37%
5 Year Return
+304.32%
10 Year Return
+4,927.96%
AUM
$1.29B
AUM Growth
+$1.29B
(-1.2%)
Cap. Flow
-$22M
Cap. Flow
% of AUM
-1.7%
Top 10 Holdings %
Top 10 Hldgs %
69%
Holding
47
New
3
Increased
3
Reduced
4
Closed
1
Top Buys
| 1 |
Sagimet Biosciences
SGMT
|
$27.1M |
| 2 |
Gossamer Bio
GOSS
|
$10.2M |
| 3 |
Geron
GERN
|
$3.03M |
| 4 |
Savara
SVRA
|
$1.26M |
| 5 |
IMA
ImageneBio, Inc. Common Stock
IMA
|
$707K |
Top Sells
| 1 |
BGRY
Berkshire Grey, Inc. Class A Common Stock
BGRY
|
$53.8M |
| 2 |
Synlogic
SYBX
|
$8.6M |
| 3 |
AKTX
Akari Therapeutics
AKTX
|
$1.7M |
| 4 |
Acrivon Therapeutics
ACRV
|
$492K |
| 5 |
EAR
Eargo, Inc. Common Stock
EAR
|
$263K |
Sector Composition
| 1 | Healthcare | 74.22% |
| 2 | Consumer Staples | 18.57% |
| 3 | Technology | 3.84% |
| 4 | Industrials | 2.91% |
| 5 | Communication Services | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Coursera
COUR
$1.88B
| $240M | 18.57% |
12,867,769
| – | – |
|
2
Arcellx
ACLX
$3.85B
| $134M | 10.38% |
3,745,262
| – | – |
|
|
3
Savara
SVRA
$567M
| $92.5M | 7.14% |
24,471,264
+333,333
| +1% | +$1.26M |
|
|
VRNA
4
Verona Pharma
VRNA
$9.16B
| $91M | 7.03% |
5,108,563
| – | – |
|
5
CRISPR Therapeutics
CRSP
$4.71B
| $72.1M | 5.57% |
1,587,854
| – | – |
|
6
Mirum Pharmaceuticals
MIRM
$3.71B
| $69.1M | 5.34% |
2,186,243
| – | – |
|
7
Rhythm Pharmaceuticals
RYTM
$6.85B
| $66.7M | 5.15% |
2,909,956
| – | – |
|
|
8
Geron
GERN
$893M
| $48.3M | 3.73% |
22,776,409
+1,428,571
| +7% | +$3.03M |
|
9
NextNav
NN
$2.37B
| $42.1M | 3.25% |
8,189,156
| – | – |
|
10
Monte Rosa Therapeutics
GLUE
$296M
| $36.8M | 2.85% |
7,692,298
| – | – |
|
|
OKUR
11
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $36.4M | 2.81% |
4,785,494
| – | – |
|
12
CVRx
CVRX
$205M
| $36M | 2.78% |
2,370,542
| – | – |
|
13
Celcuity
CELC
$2.17B
| $31.8M | 2.46% |
1,250,001
| – | – |
|
14
Aurinia Pharmaceuticals
AUPH
$1.58B
| $30.8M | 2.38% |
3,969,834
| – | – |
|
|
15
Sagimet Biosciences
SGMT
$244M
| $27.1M | 2.09% |
+3,850,275
| New | +$27.1M |
|
16
Trevi Therapeutics
TRVI
$883M
| $24.8M | 1.91% |
11,370,376
| – | – |
|
|
DM
17
DELISTED
Desktop Metal, Inc.
DM
| $21M | 1.62% |
14,407,594
| – | – |
|
18
X4 Pharmaceuticals
XFOR
$84.2M
| $16.3M | 1.26% |
14,986,793
| – | – |
|
19
NeueHealth
NEUE
$59.2M
| $16.3M | 1.26% |
2,726,917
| – | – |
|
|
ZFOX
20
DELISTED
ZeroFox Holdings, Inc. Common Stock
ZFOX
| $15.9M | 1.23% |
18,068,513
| – | – |
|
|
ALLK
21
DELISTED
Allakos
ALLK
| $14M | 1.08% |
6,147,260
| – | – |
|
|
ADAP
22
Adaptimmune Therapeutics
ADAP
$15.6M
| $13.3M | 1.03% |
17,079,778
| – | – |
|
|
23
Gossamer Bio
GOSS
$562M
| $13.1M | 1.01% |
15,727,942
+12,260,536
| +354% | +$10.2M |
|
24
Black Diamond Therapeutics
BDTX
$157M
| $12.8M | 0.99% |
4,448,757
| – | – |
|
25
Phathom Pharmaceuticals
PHAT
$864M
| $12.2M | 0.95% |
1,276,595
| – | – |
|